Navigation Links
EpiCept Reports Second Quarter 2013 Operating and Financial Results
Date:7/31/2013

property. These factors and other material risks are more fully discussed in our periodic reports, including our reports on Forms 8-K, 10-Q and 10-K and other filings with the U.S. Securities and Exchange Commission. You are urged to carefully review and consider the disclosures found in our filings which are available at www.sec.gov or at www.epicept.com. You are cautioned not to place undue reliance on any forward-looking statements, any of which could turn out to be wrong due to inaccurate assumptions, unknown risks or uncertainties or other risk factors.Selected financial information follows:EpiCept Corporation and Subsidiaries(Unaudited)Selected Consolidated Balance Sheet Data(in $000s)June 30,December 31,20132012Cash and cash equivalents

$
200

$
72Property and equipment, net

36

56Total assets

$
960

$
,328Accounts payable and other accrued liabilities

$
4,801

$
3,512Deferred revenue

7,662

7,810Notes and loans payable

4,040

3,975Total stockholders' deficit

(16,181)

(13,969)Total liabilities and stockholders' deficit

$
960

$
,328 EpiCept Corporation and Subsidiaries(Unaudited)Selected Consolidated Statement
'/>"/>

SOURCE EpiCept Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
2. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
3. Interleukin Genetics Reports Third Quarter 2011 Financial Results
4. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
5. Nile Therapeutics Reports 2011 Third Quarter Financial Results
6. Pharmasset Reports Fiscal Year End 2011 Financial Results
7. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
8. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
9. WaferGen Reports Third Quarter 2011 Financial Results and Announces New Commercialization Strategy
10. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
11. Biodel Reports Fourth Quarter Fiscal Year 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... As pet owners drew up their lists of New Year,s ... better care of my furry companion." Nowadays there are pet salons, ... cases to take the little canine or feline darlings along wherever ... buy some pricey toys at the pet store. But anyone who ...
(Date:1/14/2014)... DIEGO and BETHESDA, Md. ... are joining together with two institutes from the National ... reliable tools for bringing safer, more effective treatments to ... the National Center for Advancing Translational Sciences (NCATS) and ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... USA, and Cardiff, UK (PRWEB) January 13, 2014 ... technology development leader with more than 20 years in ... for optics and photonics . Hainsey will serve as ... delighted to have Dr. Hainsey join SPIE as our ...
Breaking Biology Technology:New Year's Resolution: Give Pets the Gift of Top-Notch Health Care 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... MAISONS-ALFORT, France, April 14 /PRNewswire-FirstCall/,-- Cephalon, Inc. (Nasdaq: ... has granted marketing authorization for EFFENTORA(TM), a buccal,tablet ... treatment of,breakthrough cancer pain (BTCP) in adult patients ... pain. The approval allows Cephalon,to market EFFENTORA in ...
... blood-based ColonSentry(TM) test -, TORONTO, April 14 ... on developing blood-based biomarker tests for the early,detection ... performance results from a large validation study of ... patient,s current risk for,colorectal cancer. This panel forms ...
... ImaRx Therapeutics,Inc. (Nasdaq: IMRX ) today announced ... 11, 2008 indicating that for the last 30,consecutive business ... closed,below $1.00 per share. As a result, the company ... continued listing set forth in,Marketplace Rule 4310(c)(4)., In ...
Cached Biology Technology:Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 2Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 3Cephalon Announces European Commission Approval of EFFENTORA for the Treatment of Breakthrough Cancer Pain 4GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 2GeneNews reports positive results from validation study of colorectal cancer biomarkers in late-breaking abstract at AACR 3ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQ's Minimum Bid Price Requirement 2
(Date:4/17/2014)... 2014The development of stem cell therapies to cure a ... stem cell populations based on cell surface markers. Researchers ... marker that is highly expressed in a type of ... they describe in an article in BioResearch Open ... Inc., publishers. The article is available free on the ...
(Date:4/17/2014)... cartridge developed at Sandia National Laboratories and recently licensed ... and cheaper. , Bacillus anthracis , the ... all over the world and can cause serious, and ... bacteria can survive in harsh conditions for decades. In ... through skin contact, inhalation of spores or eating contaminated ...
(Date:4/17/2014)... to produce hydrogen sulfide in order to properly multiply ... from the Center for Craniofacial Molecular Biology at the ... Songtao Shi, principal investigator on the project, said the ... the flow of calcium ions. The essential ions activate ... or the creation of new bone tissue, and keeps ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... 9, 2009 A nutritionist whose research was instrumental in ... Children (WIC) food subsidy will receive the March of Dimes ... maternal-fetal nutrition. Gail Harrison, Ph.D., MNS, , ... the University of California, Los Angeles School of Public Health, ...
... 150th anniversary this month of the publication of On ... Sciences (AIBS) is publishing open access two peer-reviewed articles ... , The two articles are by Kevin Padian of ... of Western Carolina University. Padian,s article, "Ten Myths About ...
... Conn.Researchers at Yale University have developed synthetic molecules capable ... HIV-infected cells, as well as to prostate cancer cells. ... the American Chemical Society , could lead to novel ... called "antibody-recruiting molecule targeting HIV" (ARM-H) and "antibody-recruiting ...
Cached Biology News:March of Dimes honors Dr. Gail Harrison for outstanding work in maternal-fetal nutrition 2New synthetic molecules trigger immune response to HIV and prostate cancer 2
... Science, which pioneered the blending of thermostable ... and Expand Long Template PCR Systems, now ... the first product of a family ... blend combines Taq DNA Polymerase with a ...
The HEPTEST assays provide a sensitive, simple, rapid, and convenient in vitro quantitation of heparin, low molecular weight heparins, and heparinoids in plasma and whole blood. Sample Type: wh...
...
... enzyme mix (Thermoprime Plus DNA Polymerase with ... four times higher fidelity than standard Taq ... Taq DNA polymerase, Amplifies DNA templates >20kb, ... PCR, PCR for cloning and mutagenesis We ...
Biology Products: